Mezzion Pharma Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2002-01-01
- Employees
- 21
- Market Cap
- -
- Website
- http://www.mezzion.co.kr
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Mezzion Pharma Co. Ltd
- Target Recruit Count
- 436
- Registration Number
- NCT05918211
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's, Little Rock, Arkansas, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
Evaluation of Fontan-Associated Liver Disease
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Mezzion Pharma Co. Ltd
- Target Recruit Count
- 88
- Registration Number
- NCT03430583
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Nemours Cardiac Center/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
A Extension Study of Udenafil in Adolescents
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Mezzion Pharma Co. Ltd
- Target Recruit Count
- 300
- Registration Number
- NCT03013751
- Locations
- 🇺🇸
Phoenix Children's Hospital/Children's Heart Center at Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Cedars/Sinai Heart Institute, Los Angeles, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
Fontan Udenafil Exercise Longitudinal Assessment Trial
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Mezzion Pharma Co. Ltd
- Target Recruit Count
- 400
- Registration Number
- NCT02741115
- Locations
- 🇺🇸
Phoenix Children's Hospital/Children's Heart Center at Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Cedars/Sinai Heart Institute, Los Angeles, California, United States
Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents
- Conditions
- Single Ventricle Heart Disease After Fontan Surgery
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Mezzion Pharma Co. Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT02201342
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸University of Michigan Congenital Heart Center, Ann Arbor, Michigan, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
News
Mezzion Secures $20 Million to Advance Phase 3 Trial of Udenafil for Rare Congenital Heart Disease
Mezzion Pharma secured approximately $20 million in strategic funding led by Midas-Meritz New Technology Finance Association to support the ongoing global Phase 3 FUEL-2 trial of udenafil for Fontan circulation patients.